| pubmed-article:17995941 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:17995941 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:17995941 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17995941 | pubmed:dateCreated | 2008-4-15 | lld:pubmed |
| pubmed-article:17995941 | pubmed:abstractText | Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits. Recently, Italian investigators reported that etoposide and epirubicin combination (EE) chemotherapy was highly active against AHCC, with a response rate of 39% and a median overall survival (OS) of 10 months. We report our efficacy and safety results of EE in clinical practice. | lld:pubmed |
| pubmed-article:17995941 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17995941 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17995941 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17995941 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17995941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17995941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17995941 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17995941 | pubmed:month | May | lld:pubmed |
| pubmed-article:17995941 | pubmed:issn | 1440-1746 | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:KimTae-WonTW | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:KangYoon-KooY... | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:LeeJung SJS | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:LeeJae-LyunJL | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:RyuMin-HeeMH | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:ChangHeung... | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:LeeSung SSS | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:SymSun JSJ | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:KimMin KMK | lld:pubmed |
| pubmed-article:17995941 | pubmed:author | pubmed-author:KimKang MKM | lld:pubmed |
| pubmed-article:17995941 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17995941 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:17995941 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17995941 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17995941 | pubmed:pagination | 811-6 | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:meshHeading | pubmed-meshheading:17995941... | lld:pubmed |
| pubmed-article:17995941 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17995941 | pubmed:articleTitle | Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. | lld:pubmed |
| pubmed-article:17995941 | pubmed:affiliation | Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. | lld:pubmed |
| pubmed-article:17995941 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17995941 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17995941 | lld:pubmed |
